Glenmark Pharma shares rise as it is set to launch anaesthetic drug in US market

Shares of Glenmark Pharmaceuticals Ltd. gained on Thursday, October 23, after the company said its US subsidiary, Glenmark Pharmaceuticals Inc., is set to launch Ropivacaine Hydrochloride Injection USP in the American market.

The product will be available in 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL) single-dose vials.

The injection is bioequivalent and therapeutically equivalent to Naropin injection, manufactured by Fresenius Kabi USA, LLC, Glenmark Pharmaceuticals said.

Ropivacaine injection is used to numb an area of the body before or during surgery or childbirth. It can also be used to relieve sudden or severe pain. The injectable is used as an anaesthetic drug to numb specific areas of the body before or during surgery or childbirth and to relieve acute pain.

Glenmark Pharmaceuticals Inc. plans to begin distribution of the drug in November 2025.

According to IQVIA sales data for the 12-month period ending August 2025, the Naropin Injection market achieved annual sales of approximately $20.9 million.

“This launch represents another important addition to Glenmark’s expanding injectable portfolio and reinforces our dedication to bring quality and affordable alternatives to market for patients in need," Marc Kikuchi, President and Business Head, North America, said.

Glenmark’s Ropivacaine Hydrochloride Injection is approved only for the indications listed in its approved label.

Shares of Glenmark Pharma were trading at ₹1,871 apiece, up 0.82%, on the BSE at around 10:30am.

Also Read: Infosys shares gain up to 5% after promoters opt out of ₹18,000 crore share buyback